

Initial Seracam® characterization results presented at Cancer Diagnosis Network Theranostics Workshop

London, UK, 22 Nov 2022. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, today announces that an abstract titled ‘Initial characterization of the Seracam: a small-footprint gamma-optical camera, with fully automated collimator changing capabilities’ has been selected for poster presentation at the Science and Technology Facilities Council funded, Cancer Diagnosis Network Theranostics Workshop on 22 November 2022, in London, UK.

Dr Sarah Bugby, Lecturer in Physics, Loughborough University and scientific expert for the characterization work being carried out on Seracam®, said:

“These initial findings show that Seracam represents a real breakthrough in the development of small field of view gamma-optical camera systems. By successfully miniaturising the planar functionality of current large field of view gamma cameras, Seracam offers the possibility of extending nuclear imaging capabilities to patients beyond the confines of a nuclear medicine department. Its use in diagnosis has the potential to bring significant benefits in terms of speed, access and affordability.”

Mark Rosser, Chief Executive Officer of Serac Imaging Systems, said:

“These encouraging results from the characterization of Seracam’s imaging performance demonstrate its potential to improve workflows in the nuclear medicine department. This, in combination with its hybrid optical imaging capabilities, portability and small size, give Seracam the potential to extend the benefits of this important imaging modality to new patient groups in new locations. We look forward continuing our work with Loughborough University as we move towards further clinical testing.”

About Seracam®

Seracam® is an innovative, compact and highly portable hybrid optical/gamma camera which is in development to bring the benefits of high-resolution molecular imaging to a patient’s bedside. This breakthrough technology will enable users to see the uptake of targeted tracers, labelled with minute amounts of radioactivity, to patients in a wide range of settings: an operating room, an intensive care unit, or a physician’s office. Currently the benefits of such imaging are largely confined to patients who can be referred to a hospital’s nuclear medicine department where the large, heavy and expensive conventional gamma cameras are sited in a fixed position in a dedicated room.

A further unique feature of Seracam®, is the combination of a gamma image overlaid with a co-aligned optical image of the same region of interest. This adds further information regarding the precise anatomical location of the molecular imaging tracer and could be used to aid the discussion between the physician and patient regarding their condition and the optimal treatment path.

About the Cancer Diagnosis Network

The Cancer Diagnosis Network is a multidisciplinary community brought together to address challenges in the diagnosis of cancer. Their work is funded by the Science and Technology Facilities Council, a United Kingdom government agency that carries out research in science and engineering, and funds UK research in areas including particle physics, nuclear physics, space science and astronomy.

- ENDS -

For more information, please contact:

Serac Imaging Systems Ltd

www.seracimagingsystems.com

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Notes to Editors

About Serac Imaging Systems

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma/optical camera for medical imaging. Our lead product is Seracam[®] which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions. Seracam[®] is a UK and EU registered trademark.

Seracam[®] is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingsystems.com

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.